UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.164

Sortiert nach

Current standards of care for chemotherapy of optimally cytoreduced advanced epithelial ovarian cancer

Gynecologic oncology, 2013-10, Vol.131 (1), p.241-245

Markman, Maurie

2013

Link zum Volltext

Verfügbarkeit prüfen

Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies

Trends in pharmacological sciences (Regular ed.), 2008-10, Vol.29 (10), p.515-519

Markman, Maurie

2008

Link zum Volltext

Verfügbarkeit prüfen

Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer

Women's Health, 2018-01, Vol.14, p.1745505717750694-1745505717750694

Markman, Maurie

2018

Link zum Volltext

Verfügbarkeit prüfen

Intraperitoneal antineoplastic drug delivery: rationale and results

The lancet oncology, 2003-05, Vol.4 (5), p.277-283

Markman, Maurie

2003

Link zum Volltext

Verfügbarkeit prüfen

Ovarian cancer

The Lancet (British edition), 2009-10, Vol.374 (9698), p.1371-1382

2009

Link zum Volltext

Verfügbarkeit prüfen

Risk of cervical cancer after HPV vaccination

Current pharmaceutical design, 2013-03, Vol.19 (8), p.1488

Markman, Maurie

2013

Link zum Volltext

Verfügbarkeit prüfen

Role of nutritional status in predicting quality of life outcomes in cancer--a systematic review of the epidemiological literature

Nutrition journal, 2012-04, Vol.11 (1), p.27-27, Article 27

2012

Link zum Volltext

Verfügbarkeit prüfen

Pharmaceutical Management of Ovarian Cancer: Current Status

Drugs (New York, N.Y.), 2019-07, Vol.79 (11), p.1231-1239

Markman, Maurie

2019

Link zum Volltext

Verfügbarkeit prüfen

Cardio-Oncology: mechanisms of cardiovascular toxicity [version 1; peer review: 2 approved]

F1000 research, 2018, Vol.7, p.113-113

2018

Link zum Volltext

Verfügbarkeit prüfen

Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary

Expert opinion on pharmacotherapy, 2006-08, Vol.7 (11), p.1469-1474

Markman, Maurie

2006

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

Journal of clinical oncology, 2007-08, Vol.25 (24), p.3621-3627

2007

Link zum Volltext

Verfügbarkeit prüfen

New, Expanded, and Modified Use of Approved Antineoplastic Agents in Ovarian Cancer

The oncologist (Dayton, Ohio), 2007-02, Vol.12 (2), p.186-190

Markman, Maurie

2007

Link zum Volltext

Verfügbarkeit prüfen

Cardio-oncology: management of cardiovascular toxicity [version 1; peer review: 2 approved]

F1000 research, 2019, Vol.8, p.120

2019

Link zum Volltext

Verfügbarkeit prüfen

Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer

Journal of clinical oncology, 2010-08, Vol.28 (22), p.3570-3576

2010

Link zum Volltext

Verfügbarkeit prüfen

Safety Issues in Using Complementary and Alternative Medicine

Journal of clinical oncology, 2002-09, Vol.20 (suppl 1), p.39s-41s

MARKMAN, Maurie

2002

Link zum Volltext

Verfügbarkeit prüfen

Phase III Trial of Ifosfamide With or Without Paclitaxel in Advanced Uterine Carcinosarcoma: A Gynecologic Oncology Group Study

Journal of clinical oncology, 2007-02, Vol.25 (5), p.526-531

2007

Link zum Volltext

Verfügbarkeit prüfen

Phase II trial of weekly paclitaxel (80 mg/m 2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study

Gynecologic oncology, 2006-06, Vol.101 (3), p.436-440

2006

Link zum Volltext

Verfügbarkeit prüfen

Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse

Clinical cancer research, 2010-02, Vol.16 (4), p.1289-1297

2010

Link zum Volltext

Verfügbarkeit prüfen

Maintenance chemotherapy in the management of epithelial ovarian cancer

Cancer and metastasis reviews, 2015-03, Vol.34 (1), p.11-17

Markman, Maurie

2015

Link zum Volltext

Verfügbarkeit prüfen

The Evolving Arena of Ovarian Cancer Maintenance Therapy

Oncology, 2019-09, Vol.97 (4), p.1-205

Markman, Maurie

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients With Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial

Journal of clinical oncology, 2003-07, Vol.21 (13), p.2460-2465

2003

Link zum Volltext

Verfügbarkeit prüfen

Duration of Response to Second-Line, Platinum-Based Chemotherapy for Ovarian Cancer: Implications for Patient Management and Clinical Trial Design

Journal of clinical oncology, 2004-08, Vol.22 (15), p.3120-3125

2004

Link zum Volltext

Verfügbarkeit prüfen

Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin

Therapeutics and clinical risk management, 2009-02, Vol.5 (1), p.161-168

Markman, Maurie

2009

Link zum Volltext

Verfügbarkeit prüfen

Lenvatinib Real-Life Experience

Oncology, 2019-01, Vol.97 (4), p.189-190

Markman, Maurie

2019

Link zum Volltext

Verfügbarkeit prüfen

Clinical Cancer Advances 2009: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology

Journal of clinical oncology, 2009-12, Vol.27 (35), p.6052-6069

2009

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.164

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(780)
Mit Volltextzugriff
(1.057)

Publikationsform

Artikel
(827)
Buchkapitel
(291)
Berichte
(26)
Bücher
(17)
Tagungsberichte
(1)
Reviews
(1)
Texte
(1)

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(1.162)
Japanisch
(70)
Deutsch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(712)
Life Sciences & Biomedicine
(708)
Oncology
(661)
Humans
(590)
Female
(416)
Ovarian Neoplasms - Drug Therapy
(224)
Biological And Medical Sciences
(180)
Medical Sciences
(180)
Middle Aged
(176)
Obstetrics & Gynecology
(173)
Aged
(152)
Chemotherapy
(151)
Ovarian Cancer
(134)
Adult
(120)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(120)
Pharmacology. Drug Treatments
(113)
Antineoplastic Agents
(102)
Antineoplastic Agents - Therapeutic Use
(94)
Tumors
(84)
Ovarian Neoplasms - Pathology
(70)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Gynecologic Oncology
(156)
Journal Of Clinical Oncology
(95)
Journal Of Cancer Research And Clinical Oncology
(81)
Oncology
(54)
Cancer
(51)
Current Oncology Reports
(49)
Case Reports In Oncology
(24)
Oncology Live
(24)
Cancer Investigation
(17)
Seminars In Oncology
(16)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Current standards of care for chemotherapy of optimally cytoreduced advanced epithelial ovarian cancer

Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies

Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer

Intraperitoneal antineoplastic drug delivery: rationale and results

Ovarian cancer

Risk of cervical cancer after HPV vaccination

Role of nutritional status in predicting quality of life outcomes in cancer--a systematic review of the epidemiological literature

Pharmaceutical Management of Ovarian Cancer: Current Status

Cardio-Oncology: mechanisms of cardiovascular toxicity [version 1; peer review: 2 approved]

Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary

Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

New, Expanded, and Modified Use of Approved Antineoplastic Agents in Ovarian Cancer

Cardio-oncology: management of cardiovascular toxicity [version 1; peer review: 2 approved]

Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer

Safety Issues in Using Complementary and Alternative Medicine

Phase III Trial of Ifosfamide With or Without Paclitaxel in Advanced Uterine Carcinosarcoma: A Gynecologic Oncology Group Study

Phase II trial of weekly paclitaxel (80 mg/m 2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study

Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse

Maintenance chemotherapy in the management of epithelial ovarian cancer

The Evolving Arena of Ovarian Cancer Maintenance Therapy

Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients With Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial

Duration of Response to Second-Line, Platinum-Based Chemotherapy for Ovarian Cancer: Implications for Patient Management and Clinical Trial Design

Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin

Lenvatinib Real-Life Experience

Clinical Cancer Advances 2009: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology

Suchergebnisse filtern